UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annals of the rheumatic diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 990 - 999
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Certolizumab Pegol | Humans | Middle Aged | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Methotrexate - therapeutic use | Polyethylene Glycols - therapeutic use | Interleukin-12 Subunit p40 - antagonists & inhibitors | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Psoriatic - drug therapy | Treatment Failure | Adult | Female | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Double-Blind Method | Immunoglobulin G - therapeutic use | Treatment Outcome | Cross-Over Studies | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Care and treatment | Usage | Psoriatic arthritis | Heart attacks | Tuberculosis | Psoriasis | Mortality | Response rates | Gangrene | Tumor necrosis factor-TNF | Arthritis | Pharmaceutical industry | Drug dosages | Quality of life | Index Medicus | Anti-TNF | Clinical and Epidemiological Research | 1506 | Spondyloarthritis | Psoriatic Arthritis
Journal Article
Arthritis & rheumatology (Hoboken, N.J.), ISSN 2326-5191, 01/2019, Volume 71, Issue 1, pp. 5 - 32
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Occupational Therapy | Arthritis, Psoriatic - epidemiology | Glucocorticoids - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Inflammatory Bowel Diseases - epidemiology | Exercise | Societies, Medical | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Physical Therapy Modalities | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Enthesopathy - therapy | Comorbidity | Spondylitis - therapy | Evidence-Based Medicine | Ustekinumab - therapeutic use | Adalimumab - therapeutic use | Interleukin-17 - antagonists & inhibitors | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Weight Loss | Abatacept - therapeutic use | Diabetes Mellitus - epidemiology | Diabetes Mellitus - therapy | Inflammatory Bowel Diseases - therapy | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Arthritis, Psoriatic - therapy | Etanercept - therapeutic use | Smoking Cessation | Index Medicus | Abridged Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 6, pp. 1869 - 1884
Immunocytokine | Tumor necrosis therapy | T cells | Immunotherapy | Interleukin-12 | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Recombinant Fusion Proteins - immunology | Recombinant Fusion Proteins - pharmacology | Humans | Recombinant Fusion Proteins - therapeutic use | Macaca fascicularis | Interferon-gamma - metabolism | Indoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | CD8-Positive T-Lymphocytes | Cancer Vaccines - therapeutic use | Immunoglobulin G - immunology | Pyrroles - administration & dosage | Protein Engineering | Immunoglobulin G - pharmacology | Female | Interleukin-12 - therapeutic use | Interleukin-12 - pharmacology | Immunomodulation | Cancer Vaccines - administration & dosage | Mice, Inbred C57BL | Neoplasms, Experimental - therapy | Immunoglobulin G - therapeutic use | Survival Rate | Tumor Burden | Antineoplastic Combined Chemotherapy Protocols - immunology | Taxoids - administration & dosage | Animals | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphocyte Activation - drug effects | Interleukin-12 - immunology | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2007, Volume 13, Issue 16, pp. 4677 - 4685
T lymphocytes | tumor immunity | dendritic cells | Interleukin-12 | angiogenesis | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Genetic Therapy | Adjuvants, Immunologic - pharmacology | Interleukin-12 - genetics | Humans | Vaccination | Interleukin-12 - physiology | Angiogenesis Inhibitors - pharmacology | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Immunity, Innate | Neoplasms - drug therapy | Animals | Angiogenesis Inhibitors - therapeutic use | Interleukin-12 - therapeutic use | Interleukin-12 - pharmacology | Index Medicus
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 4/2011, Volume 12, Issue 2, pp. 113 - 125
Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | Research-and-development | Interleukin-17-receptor- antagonists, therapeutic use | Ustekinumab, adverse reactions | AMG-827, therapeutic use | Briakinumab, therapeutic use | Psoriatic-arthritis, treatment | Interleukin-23-inhibitors, therapeutic use | LY-2439821, therapeutic use | Interleukin-12-inhibitors, therapeutic use | LY-2525623, therapeutic use | Psoriasis, treatment | Ustekinumab, therapeutic use | Apilimod, therapeutic use | Secukinumab, therapeutic use | Life Sciences & Biomedicine | Science & Technology | Biological and medical sciences | Medical sciences | Psoriasis - immunology | Psoriasis - drug therapy | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Ustekinumab | Dermatologic Agents - adverse effects | Interleukin-23 - immunology | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Animals | Arthritis, Psoriatic - immunology | Arthritis, Psoriatic - drug therapy | Interleukin-12 - immunology | Dermatologic Agents - pharmacology | Physiological aspects | Research | Interleukins | Psoriasis | Drug therapy | Risk factors
Journal Article
Gastroenterology clinics of North America, ISSN 0889-8553, 09/2017, Volume 46, Issue 3, pp. 577 - 588
Inflammatory bowel diseases | Crohn's disease | Immunology | Target therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Th1 Cells - immunology | Cell Adhesion Molecules - metabolism | Crohn Disease - immunology | Integrins - metabolism | Ustekinumab - therapeutic use | Interleukin-23 - immunology | Cell Movement - immunology | Leukocytes - immunology | Signal Transduction - immunology | Janus Kinase Inhibitors - therapeutic use | Endothelium, Vascular - metabolism | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Crohn Disease - drug therapy | Natalizumab - therapeutic use | Gastrointestinal Agents - therapeutic use | Interleukin-12 - immunology | Th17 Cells - immunology | Janus Kinases - immunology | Interleukin-12 Subunit p40 - immunology | Pyrroles - therapeutic use | Immunologic Factors - therapeutic use | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2010, Volume 362, Issue 2, pp. 118 - 128
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Dermatology | Psoriasis. Parapsoriasis. Lichen | Severity of Illness Index | Psoriasis - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Immunologic Factors - administration & dosage | Immunoglobulin G - therapeutic use | Ustekinumab | Antibodies, Monoclonal - therapeutic use | Male | Receptors, Tumor Necrosis Factor - administration & dosage | Immunoglobulin G - administration & dosage | Receptors, Tumor Necrosis Factor - therapeutic use | Antibodies, Monoclonal, Humanized | Etanercept | Antibodies, Monoclonal - administration & dosage | Interleukin-23 - antagonists & inhibitors | Interleukin-12 - antagonists & inhibitors | Adult | Female | Immunosuppressive Agents - administration & dosage | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Immunologic Factors - therapeutic use | Dosage and administration | Psoriasis | Comparative analysis | Drug therapy | Fees & charges | Cytokines | Stock options | Laboratories | Research & development--R&D | Equity | Interleukin 23 | Interleukin 12 | Tumor necrosis factor-α | Light therapy | Patients | Studies | Tumor necrosis factor-TNF | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Crohn's and colitis, ISSN 1873-9946, 2018, Volume 12, Issue 1, pp. 105 - 119
Inflammatory bowel disease | Therapy | TNF antagonists | Sphingosine-1 phosphate | IL-23 antagonists | JAK inhibitors | Smad7 | Pipeline | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Immunoglobulins | Antibodies, Monoclonal, Humanized - therapeutic use | Smad7 Protein - antagonists & inhibitors | Humans | Immunosuppressive Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Adrenal Cortex Hormones - therapeutic use | Molecular Targeted Therapy | Janus Kinases - antagonists & inhibitors | Algorithms | Interleukin-23 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Crohn Disease - drug therapy | Interleukin-12 - antagonists & inhibitors | Vascular Cell Adhesion Molecule-1 - antagonists & inhibitors | Colitis, Ulcerative - drug therapy | Drug Therapy, Combination | Mucoproteins - antagonists & inhibitors | Integrins - antagonists & inhibitors | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Index Medicus
Journal Article